Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.

abstract：:Uterine sarcomas are rare tumors constituting 1-3% of all uterine malignancies. These tumors are characterized by aggressive growth and by poor overall prognosis. There is much controversy concerning diagnostic criteria and the great variation in histology, as well as the role of radiotherapy and chemotherapy in the m...

journal_title：Anti-cancer drugs

authors： Meden H,Meyer-Rath D,Schauer A,Kuhn W

更新日期：1991-02-01 00:00:00

abstract：:Targeting of cytotoxic agents represents a modern approach to the treatment of various cancers, that improves the efficacy and reduces peripheral toxicity. Recently we developed a powerful cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AN-207, designed to be targeted to tumors that express LHRH rece...

journal_title：Anti-cancer drugs

authors： Arencibia JM,Schally AV,Halmos G,Nagy A,Kiaris H

更新日期：2001-01-01 00:00:00

abstract：:C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Between April 2008 and December 2014, 40 consecutive patients with metastatic RCC wer...

journal_title：Anti-cancer drugs

authors： Fujita T,Nishi M,Tabata K,Matsumoto K,Yoshida K,Iwamura M

更新日期：2016-11-01 00:00:00

abstract：:We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer. Medical care consumption data were collected prospective...

journal_title：Anti-cancer drugs

authors： Schmitt C,Blijham G,Jolain B,Rougier P,Van Cutsem E

更新日期：1999-07-01 00:00:00

abstract：:Cryptophycin (CP)-52, a synthetic analog of CP-1, possesses potent and selective antiproliferative activity against human solid tumors both and. Based on an algorithm developed in this laboratory using HCT-116 human colon adenocarcinoma cells, CP-52 exhibited a time- and concentration-dependent antiproliferative effec...

journal_title：Anti-cancer drugs

authors： Subramanian B,Nakeff A,Media JE,Wiegand RA,Valeriote FA

更新日期：2002-11-01 00:00:00

abstract：:Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which falls to take into account the known heterogeneity of chemosensitivity between patients. Previous attempts to determine chemosensitivity ex vivo have been disappointing, but in this study results from ...

journal_title：Anti-cancer drugs

authors： Cree IA,Kurbacher CM,Untch M,Sutherland LA,Hunter EM,Subedi AM,James EA,Dewar JA,Preece PE,Andreotti PE,Bruckner HW

更新日期：1996-08-01 00:00:00

abstract：:5-Fluorouracil (5-FU) is the most widely used agent for the management of colorectal cancer. Capecitabine is metabolized by three enzymatic actions, the last of which is mediated by thymidine phosphorylase, to produce 5-FU. Given the oral bioavailability of capecitabine as well as in-vitro and in-vivo findings showing...

journal_title：Anti-cancer drugs

authors： Patel PA

更新日期：2011-04-01 00:00:00

abstract：:Preoperative chemoradiotherapy (CRT) is generally performed for locally advanced rectal cancer (LARC, cStage 2 or 3) to improve local disease control and patient survival. The pathological tumor response to CRT is a surrogate marker that is associated with oncological outcome. Thus, markers that predict the response t...

journal_title：Anti-cancer drugs

authors： Roh K,Yeo SG,Yoo BC,Kim KH,Kim SY,Kim MJ

更新日期：2016-09-01 00:00:00

abstract：:We have synthesized and characterized doxorubicin (DOX)-loaded galactosylated gelatin nanovectors using in vitro and in vivo for targeting liver cells including hepatocarcinoma cells. Galactosylated and nongalactosylated gelatin nanovectors (GL-GN-DOX and GN-DOX) were spherical in shape and had mean sizes of about 95....

journal_title：Anti-cancer drugs

authors： Garg M,Madan J,Pandey RS,Sardana S,Katyal A,Chandra R

更新日期：2012-09-01 00:00:00

abstract：:Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and b...

journal_title：Anti-cancer drugs

authors： Koukourakis MI,Kakouratos C,Kalamida D,Mitrakas A,Pouliliou S,Xanthopoulou E,Papadopoulou E,Fasoulaki V,Giatromanolaki A

更新日期：2018-04-01 00:00:00

abstract：:Lipoplatin, currently under phase III evaluation, is a novel liposomal cisplatin formulation highly effective against cancers. Lipoplatin has eliminated or reduced the systemic toxicity frequently seen for cisplatin. The objective of the present study was to determine whether the cytotoxic effect of lipoplatin is depe...

journal_title：Anti-cancer drugs

authors： Fedier A,Poyet C,Perucchini D,Boulikas T,Fink D

更新日期：2006-03-01 00:00:00

abstract：:Venetoclax is a first-in-class orally available, B-cell lymphoma (BCL)-2 inhibitor indicated for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. We used a novel approach for evaluating venetoclax pharmacokinetics using only sparse sampling in 155 patien...

journal_title：Anti-cancer drugs

authors： Salem AH,Dunbar M,Agarwal SK

更新日期：2017-09-01 00:00:00

abstract：:The dose-limiting toxicities of the DNA topoisomerase I inhibitor topotecan are hematological. We prospectively analyzed the platelet toxicity pattern in patients receiving topotecan to optimize the clinical management of topotecan hematotoxicity. Twenty-one advanced ovarian cancer patients, all pretreated with cispla...

journal_title：Anti-cancer drugs

authors： Goldwasser F,Buthaud X,Gross M,Bleuzen P,Cvitkovic E,Voinea A,Jasmin C,Romain D,Misset JL

更新日期：1999-03-01 00:00:00

abstract：:Results from our previous phase II study demonstrating high efficacy and low toxicity for a weekly schedule of 5-fluorouracil (5-FU)/leucovorin in intensively pretreated patients with metastatic breast cancer prompted addition of paclitaxel and cisplatin to this regimen for a phase II study of outpatient first-line tr...

journal_title：Anti-cancer drugs

authors： Klaassen U,Wilke H,Weyhofen R,Harstrick A,Eberhardt W,Müller C,Korn M,Hanske M,Diergarten K,Seeber S

更新日期：1998-03-01 00:00:00

abstract：:Treatment of mammalian cells with chemotherapeutic drugs can result in perturbations of nucleotide pools. Monitoring these perturbations in cultured tumor cells from human sources is useful for assessment of the effect of drug therapy and a better understanding of the mechanism of action of these drugs. In this study,...

journal_title：Anti-cancer drugs

authors： Liu X,Zhang CC,Liu Z,Wei L,Liu YJ,Yu J,Sun LX

更新日期：2014-07-01 00:00:00

abstract：:The aim of this study was to investigate in a randomized trial the activity of perioperative chemotherapy in patients treated with preoperative chemotherapy for locally advanced breast cancer and to compare it with the preoperative chemotherapy alone. Patients with cT2-3 N0-2 M0 histologically proven breast cancer, wi...

journal_title：Anti-cancer drugs

authors： Rocca A,Peruzzotti G,Ghisini R,Viale G,Veronesi P,Luini A,Intra M,Pietri E,Curigliano G,Giovanardi F,Maisonneuve P,Goldhirsch A,Colleoni M

更新日期：2006-11-01 00:00:00

abstract：:In the present study we investigated the enhancement of cytotoxicity of peritoneal macrophages induced by OK-432. Rats received an i.p. injection of OK-432 at doses of 0.1, 0.5 or 1.0 KE/rat. Two days later, rats were sacrificed and peritoneal macrophages were isolated. Then the number of macrophages was counted, and ...

journal_title：Anti-cancer drugs

authors： Huang Y,Xu Y,Yamagishi H,Hagiwara A

更新日期：2001-10-01 00:00:00

abstract：:We investigated whether Ukrain modulates the malignant phenotype of clear cell renal cell carcinoma (ccRCC) cells Caki-1, Caki-2, and ACHN treated with four doses (5, 10, 20, and 40 μmol/l) for 24 and 48 h. The epithelial-to-mesenchymal transition markers E-cadherin, β-catenin, and vimentin were analyzed by immunofluo...

journal_title：Anti-cancer drugs

authors： Gagliano N,Pettinari L,Aureli M,Martinelli C,Colombo E,Costa F,Carminati R,Volpari T,Colombo G,Milzani A,Dalle-Donne I,Gioia M

更新日期：2011-09-01 00:00:00

abstract：:Continuous exposure to daunorubicin (DNR) confers resistance against the drug-elicited lethality of leukemic cells and then reduces the remission rate. However, the detailed mechanisms involved in resistance development of leukemic cells to DNR remain unclear. Upregulation of aldo-keto reductases (AKRs) in human leuke...

journal_title：Anti-cancer drugs

authors： Matsunaga T,Yamaguchi A,Morikawa Y,Kezuka C,Takazawa H,Endo S,El-Kabbani O,Tajima K,Ikari A,Hara A

更新日期：2014-09-01 00:00:00

abstract：:Mistletoe extracts are frequently applied in adjuvant cancer treatment. The mistletoe lectins are especially suggested to mediate an antitumorous effect. During treatment with mistletoe lectin-rich extracts, anti-mistletoe lectin antibodies preferentially of the immunoglobulin G type are produced against mistletoe lec...

journal_title：Anti-cancer drugs

authors： Stein GM,Stettin A,Schultze J,Berg PA

更新日期：1997-04-01 00:00:00

abstract：:Aberrant expression of the epidermal growth factor receptor (EGFR) system has been reported in a wide range of epithelial cancers. In some studies, this has also been associated with a poor prognosis and resistance to the conventional forms of therapies. These discoveries have led to the strategic development of sever...

journal_title：Anti-cancer drugs

authors： Modjtahedi H,Essapen S

更新日期：2009-11-01 00:00:00

abstract：:The antitumor effect of etoposide (ETO) may be related to duration of exposure to a relatively low serum level while myelosuppression may be dependent on peak ETO serum levels. With regard to such therapeutic ranges, duration of exposure to predefined plasma ETO concentration ranges and the related AUC (expressed as p...

journal_title：Anti-cancer drugs

authors： Würthwein G,Krümpelmann S,Tillmann B,Real E,Schulze-Westhoff P,Jürgens H,Boos J

更新日期：1999-10-01 00:00:00

abstract：:Twelve patients received intrapleural instilments of the cytostatic agent mitoxantrone in a total dosage of 30 mg for locoregional palliative therapy of malignant pleural effusion. Effusion could be stopped for a mean period of 3.2 months in 11 patients. ...

journal_title：Anti-cancer drugs

authors： Torsten U,Opri F,Weitzel H

更新日期：1992-02-01 00:00:00

abstract：:The delivery formulation 5-FU-MS [5-fluorouracil (5-FU) incorporated in microspheres composed of a poly(glycolide-co-lactide) matrix] slowly releases 5-FU over 3 weeks. 5-FU-MS delivers higher concentrations of the drug to the i.p. tissues for a longer period of time with lower blood plasma concentrations than does an...

journal_title：Anti-cancer drugs

authors： Hagiwara A,Sakakura C,Shirasu M,Yamasaki J,Togawa T,Takahashi T,Muranishi S,Hyon S,Ikada Y

更新日期：1998-03-01 00:00:00

abstract：:Cerebral gliomas have a poor survival time even after multimodal treatment, because of the unavoidable recurrence of tumor. Several trials with a combination of old and new chemotherapics have been performed, but survival time remains generally less than 12 months. Tamoxifen (TAM) has recently been shown to inhibit th...

journal_title：Anti-cancer drugs

authors： Mastronardi L,Puzzilli F,Ruggeri A

更新日期：1998-08-01 00:00:00

abstract：:Derivatives of bis-aryl urea have been widely investigated for their various biological activities, such as antiviral, anti-inflammatory and antiproliferative. We evaluated a new chemical entity consisting of bis-aryl urea moiety, N69B, for its anticancer activities and explored their underlying molecular mechanism. T...

journal_title：Anti-cancer drugs

authors： Wu J,Huang Y,Xie Q,Zhang J,Zhan Z

更新日期：2020-06-01 00:00:00

abstract：:The use of viability assays to assess the effect of antineoplastic agents on cell lines and tumor cells is an important investigative tool and may have clinical relevance. Such assays require very small quantities of drugs and it is the practice of many laboratories to freeze aliquots of drugs for use in these assays ...

journal_title：Anti-cancer drugs

authors： Hunter EM,Sutherland LA,Cree IA,Subedi AM,Hartmann D,Linder D,Andreotti PE

更新日期：1994-04-01 00:00:00

abstract：:Chemotherapy is the only option of treatment for most patients presenting with a recurrent and/or metastatic head and neck squamous cell carcinoma. The triple association of cisplatin, 5-fluorouracile, and cetuximab is still the current standard for fit patients. Other schemes are currently being compared with this pr...

journal_title：Anti-cancer drugs

authors： Karabajakian A,Toussaint P,Neidhardt EM,Paulus V,Saintigny P,Fayette J

更新日期：2017-04-01 00:00:00

abstract：:This phase I study was performed to assess the feasibility of combining cisplatin/etoposide (VP-16) with the arotinoid Ro 40-8757 and to determine the dose-limiting toxicity (DLT) of Ro 40-8757 in this combination. Patients with non-small cell lung cancer were eligible. Treatment consisted of Ro 40-8757 p.o. day 1-21,...

journal_title：Anti-cancer drugs

authors： van Zuylen L,Schellens JH,Goey SH,Pronk LC,de Boer-Dennert MM,Loos WJ,Ma J,Stoter G,Verweij J

更新日期：1999-04-01 00:00:00

abstract：:PC cell-derived growth factor is a novel growth factor for tumor formation and progression. No comprehensive literature concerning PC cell-derived growth factor expression status and its biological function in squamous cell carcinoma, especially in the larynx, is, however, available. The target of this study is to eva...

journal_title：Anti-cancer drugs

authors： Kong WJ,Zhang SL,Chen X,Zhang S,Wang YJ,Zhang D,Sun Y

更新日期：2007-01-01 00:00:00